TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32549996

Group type: EXPERIMENTAL
Intervention: Standard care plus with additional three‐monthly magnetic resonance imaging until remission up to 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Magnetic resonance imaging at baseline and remission up to 12 months, with repeated foot temperature measurements and X‐rays (standard care plus)
Number of subjects: 60
Study: 33431085

Group type: EXPERIMENTAL
Intervention: ICD‐11 PTSD diagnosis
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: ICD‐11 CPTSD diagnosis
Number of subjects: 221
Study: 34936269

Group type: EXPERIMENTAL
Intervention: Baixiao moxibustion and qiangshen shugan qiwei decoction (one dose daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: qiangshen shugan qiwei decoction (one dose daily)
Number of subjects: 120
Study: 35338035

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study: 33373667

Group type: EXPERIMENTAL
Intervention: Point of care screening (POC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct patient engagement (DPE)
Number of subjects: 0
Study: 36084331

Group type: EXPERIMENTAL
Intervention: Conventional ILM peeling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inverted flap technique
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 33229930

Group type: EXPERIMENTAL
Intervention: Lidocaine group: perioperative intravenous lidocaine infusion, plus PCA with morphine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Epidural group: PCA with bupivacaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Opioid group: patient‐controlled analgesia (PCA) with morphine
Number of subjects: 75
Study: 34213858

Group type: EXPERIMENTAL
Intervention: MMWR (Mindfulness-Based Intervention)
Number of subjects: 200
Study: 32185760

Group type: EXPERIMENTAL
Intervention: Ischemia-modified albumin (IMA) and IMA/albumin ratio (IMAR) in the 30-min shock group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischemia-modified albumin (IMA) and IMA/albumin ratio (IMAR) in the 60-min shock group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shock groups (mild and severe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of biomarkers with HS-induced damage
Number of subjects: 0
Study: 34098845

Group type: EXPERIMENTAL
Intervention: Individual fortification (IF) of mother’s breast milk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard fortification (SF) of mother’s breast milk
Number of subjects: 60
Study: 34564996

Group type: EXPERIMENTAL
Intervention: Nomograms for predicting overall survival (OS)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Nomograms for predicting cancer-specific survival (CSS)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Independent prognostic factors for OS
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Independent prognostic factors for CSS
Number of subjects: 948
Study: 34280012

Group type: EXPERIMENTAL
Intervention: GST-HG141 (300 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GST-HG141 (50 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GST-HG141 (100 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: GST-HG141
Number of subjects: 50
Study: 32334845

Group type: EXPERIMENTAL
Intervention: Biosimilar BE1040V plus FOLFIRI-3 (5 mg/kg IV every 2 weeks for 1 year)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Reference drug plus FOLFIRI-3 (dosage not specified, every 2 weeks for 1 year)
Number of subjects: 126
Study: 35421848

Group type: EXPERIMENTAL
Intervention: Cervical cancer survivor's story (short film)
Number of subjects: 2175

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 2175
Study: 34878990

Group type: EXPERIMENTAL
Intervention: Mobile app intervention (app group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care (no-app group)
Number of subjects: 83
Study: 32013647

Group type: EXPERIMENTAL
Intervention: PAD facilitation by peer support specialist
Number of subjects: 145

Group type: COMPARATOR
Intervention: PAD facilitation by non-peer ACT team clinician
Number of subjects: 145
Study: 33060092

Group type: EXPERIMENTAL
Intervention: Community-based screening programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional intervention (control)
Number of subjects: 0
Study: 35157527

Group type: EXPERIMENTAL
Intervention: Salt loading (3,900 mg sodium for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (10 days)
Number of subjects: 20
Study: 33685234

Group type: EXPERIMENTAL
Intervention: PE+T+PP (phenylephrine + tropicamide + proparacaine)
Number of subjects: 63

Group type: COMPARATOR
Intervention: T+PP (tropicamide + proparacaine)
Number of subjects: 63
Study: 32248329

Group type: EXPERIMENTAL
Intervention: BIM23B065
Number of subjects: 0
Study: 34759933

Group type: COMPARATOR
Intervention: Eptinezumab (10 to 1000 mg, administered intravenously for up to 4 doses at 12-week intervals)
Number of subjects: 2076
Study: 32931324

Group type: EXPERIMENTAL
Intervention: Comprehensive overdose education and naloxone distribution (OEND) training
Number of subjects: 787
Study: 33819350

Group type: EXPERIMENTAL
Intervention: Formula method
Number of subjects: 130

Group type: COMPARATOR
Intervention: Common method
Number of subjects: 130
Study: 32102054

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) supplementation at a dosage of 0.3 g·kg BM in gelatine capsules
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) supplementation
Number of subjects: 13
Study: 33905287

Group type: EXPERIMENTAL
Intervention: Group Therapy for Improving Emotional Acceptance and Regulatory Skills in Adults with ADHD (GEARS)
Number of subjects: 226
Study: 32484261

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training
Number of subjects: 62
Study: 36197520

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Duodenal switch (DS)
Number of subjects: 75
Study: 34006075

Group type: EXPERIMENTAL
Intervention: 100% deproteinised bovine bone matrix grafts (DBBM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100% autogenous bone grafts (AB)
Number of subjects: 40
Study: 32794282

Group type: EXPERIMENTAL
Intervention: Microwave-assisted pasteurized fried rice (MAPS)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control fried rice (cooked but not MAPS-processed)
Number of subjects: 2
Study: 32657198

Group type: EXPERIMENTAL
Intervention: Therapy Behavior Scale (TBS) Version 2.2
Number of subjects: 10
Study: 33044437

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (1.2 g·min‐1 glucose) after breakfast omission
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (1.2 g·min‐1 glucose) after breakfast consumption
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo beverage after breakfast omission
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo beverage after breakfast consumption
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage after breakfast consumption
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage after breakfast omission
Number of subjects: 11
Study: 35793536

Group type: EXPERIMENTAL
Intervention: Negative condition (consistent negative statement about e‐cigarette harms)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Smoking Risk + Conflict condition (statement of the risks of smoking followed by a harm reduction statement from one public health body and a negative statement from another)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Conflict condition (harm reduction statement from one public health body and a negative statement from another)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Harm Reduction condition (consistent harm reduction statement from two different public health bodies)
Number of subjects: 702
Study: 32131476

Group type: EXPERIMENTAL
Intervention: Cardio-protective diet and physical exercise
Number of subjects: 51

Group type: COMPARATOR
Intervention: Baseline selenium status
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SELENOP concentration
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: GPx activity
Number of subjects: 51
Study: 33290360

Group type: EXPERIMENTAL
Intervention: Notched music therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conventional music therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 75
Study: 33233750

Group type: EXPERIMENTAL
Intervention: 14-week teacher training program
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 141
Study: 35641257

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 60
Study: 32312357

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Symptom-focused CBT
Number of subjects: 223

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 223
Study: 32779529

Group type: EXPERIMENTAL
Intervention: PEOL Care Index instrument
Number of subjects: 43
Study: 35064870

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study: 34613379

Group type: EXPERIMENTAL
Intervention: Early physical therapy (PT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204
Study: 33909355

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication
Number of subjects: 134

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 134
Study: 35069580

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study: 32060567

Group type: EXPERIMENTAL
Intervention: Endovascular treatment combined with intravenous alteplase
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Endovascular treatment as single treatment
Number of subjects: 275
Study: 35896281

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 187

Group type: COMPARATOR
Intervention: Upadacitinib (after switching from placebo)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Continuous upadacitinib
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo-to-upadacitinib switch
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Total group
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 187
Study: 32885455

Group type: EXPERIMENTAL
Intervention: Risk Group (carried both rs4880 and rs1050450 at-risk alleles)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Risk Group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonrisk Group
Number of subjects: 34
Study: 32761500

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20
Study: 34587807

Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament reconstruction (MPFLr)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: MPFLr + tibial tubercle distalization (TTD)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Trochleoplasty + TTD
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Trochleoplasty
Number of subjects: 202
Study: 32905673

Group type: EXPERIMENTAL
Intervention: Continuous high-flow oxygen therapy with frequency of suctioning as the indicator of readiness for decannulation
Number of subjects: 330

Group type: COMPARATOR
Intervention: 24-hour capping trial plus intermittent high-flow oxygen therapy
Number of subjects: 330
Study: 34808142

Group type: EXPERIMENTAL
Intervention: R+L− stimulation (tDCS over bilateral DLPFC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 70
Study: 34019819

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 intravenous), carboplatin (area under the concentration–time curve 6 mg/mL per min intravenous), trastuzumab (subcutaneous 600 mg fixed dose), and pertuzumab (intravenous 840 mg loading dose, 420 mg maintenance doses)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Trastuzumab and pertuzumab (with letrozole or tamoxifen for hormone receptor-positive patients)
Number of subjects: 356
Study: 32276003

Group type: EXPERIMENTAL
Intervention: GINA + FeNO group
Number of subjects: 176

Group type: COMPARATOR
Intervention: GINA group
Number of subjects: 176
Study: 36105446

Group type: EXPERIMENTAL
Intervention: Omaha system‐based comprehensive nursing
Number of subjects: 60
Study: 34238788

Group type: EXPERIMENTAL
Intervention: Complex reconstruction (flap or graft) performed by 6 surgeons
Number of subjects: 338
Study: 32755237

Group type: EXPERIMENTAL
Intervention: Allogeneic growth factors injection
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline 0.9% injection
Number of subjects: 150
Study: 34530020

Group type: EXPERIMENTAL
Intervention: Omalizumab plus background nasal mometasone therapy for 28 weeks
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Omalizumab (after switching from placebo)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Omalizumab discontinuation
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Safety profile of omalizumab
Number of subjects: 249
Study: 33786690

Group type: EXPERIMENTAL
Intervention: Genetically predicted serum urate levels
Number of subjects: 110347
Study: 34894861

Group type: EXPERIMENTAL
Intervention: Resistance training and supplementation (whey protein and vitamin D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training and placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 33625693

Group type: EXPERIMENTAL
Intervention: Citrate buffer during high volume on-line hemodiafiltration (OL-HDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33711170

Group type: EXPERIMENTAL
Intervention: Extraradicular biofilm samples
Number of subjects: 18

Group type: COMPARATOR
Intervention: Periapical lesions
Number of subjects: 18
Study: 32331026

Group type: EXPERIMENTAL
Intervention: 200 mg SPN-812
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: 400 mg SPN-812
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 35696023

Group type: EXPERIMENTAL
Intervention: Collagen Peptide (CP) at 5.0 g/day for 3 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Collagen Peptide Fermented with Aspergillus sojae (FCP) at 5.0 g/day for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (PL) at 5.0 g/day for 3 months
Number of subjects: 44
Study: 33429063

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg sc)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 34414808

Group type: EXPERIMENTAL
Intervention: Making Your Wishes Known (MYWK) together with loved one
Number of subjects: 246

Group type: COMPARATOR
Intervention: Other control groups
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: MYWK Together
Number of subjects: 246
Study: 33434087

Group type: EXPERIMENTAL
Intervention: Listening to music during cesarean section and postpartum (Group 3)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Listening to music during cesarean section (Group 2)
Number of subjects: 185

Group type: COMPARATOR
Intervention: No music (Group 1)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Listening to music in a private ward
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Mothers with income <20,000 baht, lower than university education, planned pregnancy, first pregnancy, and stayed in a private ward
Number of subjects: 185
Study: 33313728

Group type: EXPERIMENTAL
Intervention: Integrated sequenced-care pathway
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Coordinated pain navigator pathway
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Additional surveys for a subset of veterans
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Both pathways
Number of subjects: 1680
Study: 34062085

Group type: EXPERIMENTAL
Intervention: Qingrun yogurt (250 g) once daily for 12 weeks
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control yogurt
Number of subjects: 136
Study: 33517881

Group type: EXPERIMENTAL
Intervention: Non-tourniquet group (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tourniquet group (Group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tourniquet in cementation group (Group C)
Number of subjects: 150
Study: 32341486

Group type: EXPERIMENTAL
Intervention: Sodium-reduced bread and dietary counseling (Intervention B)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Sodium-reduced bread (Intervention A)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Regular sodium bread (Control)
Number of subjects: 309
Study: 36027906

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 33673867

Group type: EXPERIMENTAL
Intervention: Telemedicine specialist
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Telemedicine non-specialist
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: In-person specialist
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: In-person non-specialist
Number of subjects: 1368

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1368
Study: 36119147

Group type: EXPERIMENTAL
Intervention: Two envelopes method of teaching
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lecture hall format (2018)
Number of subjects: 120
Study: 33277285

Group type: EXPERIMENTAL
Intervention: G-CSF + CA/CY/TBI
Number of subjects: 160

Group type: COMPARATOR
Intervention: CA/CY/TBI
Number of subjects: 160
Study: 34992119

Group type: EXPERIMENTAL
Intervention: Conditional cash transfers (CCTs) of US$4.5
Number of subjects: 5444

Group type: COMPARATOR
Intervention: Phone credit of US$0.5
Number of subjects: 5444
Study: 34255420

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 349

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 349
Study: 35489309

Group type: EXPERIMENTAL
Intervention: Continuum beliefs intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: Perceived differences from a person with depression
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Expressed continuum beliefs
Number of subjects: 304
Study: 33788456

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (flunarizine hydrochloride capsule 10 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medication (flunarizine hydrochloride capsule 10 mg/day)
Number of subjects: 120
Study: 35609291

Group type: EXPERIMENTAL
Intervention: Intensive physical therapy (twice daily coached breathing exercises for 2 days and 30 minutes of daily supervised rehabilitation over the first 5 postoperative days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 33761894

Group type: COMPARATOR
Intervention: IT morphine 0.2 mg with sham QLB (Group IT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IT morphine 0.2 mg and bilateral QLB with 0.25% bupivacaine 25 ml in each side (Group IT+QLB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bilateral QLB with 0.25% bupivacaine 25 ml in each side (Group QLB)
Number of subjects: 80
Study: 34082300

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure (SMBP)
Number of subjects: 154
Study: 34520536

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy before aerobic exercises, three sessions per week for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aerobic exercises three times weekly for 12 weeks (Control group)
Number of subjects: 60
Study: 34570156

Group type: EXPERIMENTAL
Intervention: Free gingival graft (FGG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Collagen-matrix xenograft (CMX)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Deproteinized bovine bone graft (DBBG)
Number of subjects: 16
Study: 32329742

Group type: EXPERIMENTAL
Intervention: Serious game intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (brochure about food pyramid)
Number of subjects: 82
Study: 35764103

Group type: EXPERIMENTAL
Intervention: 20% to 30% SF6 gas tamponade
Number of subjects: 144

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 144
Study: 32621368

Group type: EXPERIMENTAL
Intervention: Youth opioid recovery support (YORS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 41
Study: 35328014

Group type: EXPERIMENTAL
Intervention: 600 mg of aspirin
Number of subjects: 861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study: 34118282

Group type: EXPERIMENTAL
Intervention: 200 ppm fluoride toothpaste with sodium trimetaphosphate, xylitol, and erythritol (200F-TMP-XE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1100 ppm fluoride toothpaste (1100F)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 16% Xylitol and 4% Erythritol (XE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (no fluoride, TMP, or XE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 200 ppm fluoride toothpaste (200F)
Number of subjects: 14
Study: 32143732

Group type: EXPERIMENTAL
Intervention: Active peripheral nerve stimulation of the axillary nerve of the affected shoulder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham peripheral nerve stimulation of the axillary nerve of the affected shoulder (Control)
Number of subjects: 0
Study: 35766558

Group type: EXPERIMENTAL
Intervention: PN with iron sucrose 100 μg/kg/d (Iron-1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PN with iron sucrose 200 μg/kg/d (Iron-2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PN with iron sucrose 300 μg/kg/d (Iron-3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PN with iron sucrose 400 μg/kg/d (Iron-4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (PN without iron sucrose, Iron-0)
Number of subjects: 100
Study: 33940550

Group type: EXPERIMENTAL
Intervention: Self-compassion (SC) intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Dissonance-based (DB) intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waitlist (WL) control
Number of subjects: 151